Tissue Regenix Group PLC Publication of Financial Results (0406I)

TIDMTRX

RNS Number : 0406I

Tissue Regenix Group PLC

16 March 2018

Tissue Regenix Group plc

Publication of Financial Results

Leeds, 16 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the audit process of its annual financial statements is still ongoing and the audited results for year ended 31 December 2017 will now be announced on Monday 26 March 2018. The Board is satisfied that there are no negative issues and trading remains in line with Board expectations.

For more Information:

 
 Tissue Regenix Group plc                  Tel: 
  Caitlin Pearson Head of Communications    0330 430 
                                            3073 / 07920272 
                                            441 
----------------------------------------  ----------------- 
 Jefferies International Ltd               Tel: 
  Simon Hardy / Christopher Binks           020 7029 
                                            8000 
----------------------------------------  ----------------- 
 FTI Consulting                            Tel: 
  Brett Pollard / Mo Noonan/ Rob Winder     0203 727 
                                            1000 
========================================  ================= 
 

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORFKADNPBKDBND

(END) Dow Jones Newswires

March 16, 2018 11:40 ET (15:40 GMT)